Testing for human papillomavirus: basic pathobiology of infection, methodologies, and implications for clinical use. by Wilbur, D. C. & Stoler, M. H.
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 64 (1991), 113-125
Testing for Human Papillomavirus: Basic Pathobiology of
Infection, Methodologies, and Implications for
Clinical Use*
DAVID C. WILBUR, M.D.,a AND MARK H. STOLER, M.D.b
aDepartment ofPathology, UniversityofConnecticutHealth Center, Farmington,
Connecticut; bDepatment ofPathology, Cleveland Clinic Foundation, Cleveland, Ohio
Received December 11, 1990
New molecular biological evidence has recently emerged, strongly implicating the human
papillomavirus (HPV) as playing an etiologic role in the development of neoplasias of the
genital tract. As technologies advance, the ability to test for the presence of HPV has become
simpler, more reliable, and less expensive. A great deal ofcontroversy has arisen regarding the
effective and proper utilization of these new tests in the management of HPV infections. This
review will detail the new evidence implicating the putative role of HPV in neoplasia and the
current methodologies available for assessing the presence of HPV in clinical samples and will
describe the current controversy surrounding their utilization.
INTRODUCTION
It is estimated that there will be 13,000 incident cases of invasive cervical cancer
and 50,000 incident cases of cervical carcinoma in situ in the United States in 1991
[1]. Since the advent of mass cytologic screening programs in the 1950s, the overall
mortality of this disease has been reduced by 70 percent, but deaths continue in the
unscreened or poorly screened patient populations. Recently, a resurgence in the
number ofcases ofprecursor lesions to cervical cancer has been seen, particularly in
young, sexually active populations. Improved clinical methods for screening, diagno-
sis, and prediction are continually being sought and tested, the better to control this
preventable disease.
A growing body of epidemiologic, cytologic, and molecular biologic evidence has
linked the human papillomavirus (HPV) to cancers ofthe female genital tract. Data
show that cervical cancers have the epidemiologic characteristics of venereally
transmitted infections. HPV deoxyribonucleic acid (DNA) has been identified in the
vast majority ofspecimens from cervical and vulvar neoplastic lesions. Furthermore,
association ofparticular histologic patterns ofneoplasia with specific HPV types has
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been demonstrated. In addition, newly emerging molecular genetic data show a
potential biologic role ofpapillomaviral genes in the carcinogenesis sequence.
With this growing understanding ofthe association, and potential role ofthe virus
in carcinogenesis, particularly cervical, the ability to identify evidence of HPV
infection has been explored as a method to identify those patients at increased risk
for the subsequent development ofinvasive cancers. The ability to define further the
additional risk ofdisease progressionbyviral typing has also been postulated.
The purpose of this review will be to detail the evidence linking HPV to genital
neoplasia, the methodologies currently available to detect HPV in clinical samples,
and the clinical utility ofthevarious detection strategies.
THE ASSOCIATION OF HUMAN PAPILLOMAVIRUS WITH
GENITAL NEOPLASIA
The epidemiologic data supporting avenereal transmission pattern for condyloma
and cervical neoplasia have been well reviewed by other authors [2,3]. A variety of
infectious agents have been investigated with regard to their carcinogenic potential
in genital neoplasia. It was not until the middle 1970s, when Meisels and Fortin [4]
first recognized that the cytologically defined, pre-cancerous condition ofkoilocyto-
sis [5,6] actually represented HPV cytopathic effect, that the association of HPV in
cervical neoplasia was postulated. Classic cytologic studies had previously shown a
progression of koilocytotic lesions to dysplasias and invasive carcinoma [7]. Hence,
HPV became the prime infectious agent postulated to be etiologic in the develop-
mentoflowergenital tract neoplasia, thusspurring a tremendous research effort into
the understanding ofthis association and its mechanisms.
Prior to the ability to detect HPV via immunopathologic and molecular biologic
methods, the only way to confirm that a koilocyte was an HPV-related cell was by
electron microscopic demonstration ofvirions. Numerous investigators have shown
that, although koilocytes were identified in a high percentage of low-grade lesions,
such as condylomata and slight dysplasias (CIN I), as the epithelial maturation
abnormality increased (i.e., higher grades of dysplasia), koilocytes were found in
fewer and fewer cases [8,9]. Our present understanding of the life cycle of the HPV
explains this phenomenon, although the actual mechanism of development of
koilocytosis is presently unknown. Completion ofthe viral life cycle with production
of whole virions is most closely correlated with the cytopathic effect that we
recognize as koilocytosis. Full viral replication can only occur in the presence of an
entire intactviral genome and requireskeratinocyte maturation for full expression of
the viral life cycle. Therefore, in low-grade lesions, the host cellular environment is
permissive forproduction ofvirions, and, hence, koilocytes are more frequent. In the
higher-grade lesions, the epidermal cells lack the necessary maturation for full viral
replication, and, in addition, the phenomenon of partial viral genomic integration
into host genome may also occur. In this situation, the virus is not competent to
replicate, and viral gene expression is altered such that koilocytosis is much less
frequent.
Immunohistochemical approaches to the identification ofviral antigen present in
tissues were somewhat more productive than virion identification but still failed to
identify HPV in the majority of high-grade lesions, because the procedure detects
viral capsid antigen. Antigen production requires late gene expression,which isoften
lacking in high-grade lesions [9,10].
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With the advent ofmolecularbiologic techniques for the detection ofviral nucleic
acid molecules, it became clear how prevalent HPV DNAwas, not only in low-grade
lesions, but also in the high-grade dysplasias and invasive carcinomas. When sensi-
tive techniqueswere employed, more than 90 percent ofinvasive cervical carcinomas
of all histologic types were found to contain portions of the HPV genome [11]. Over
60 HPV types have been identified to date, with about two dozen of these having
been found to be associated with genital tract pathology. In addition, it appears that
there are certain virus types which are associated with lesions showing a low risk of
progression, most commonly viral types 6 and 11. These are the types most likely to
be found in exophytic genital condylomata [12]. Virus types 16 and 18 are the
predominant types associated with cervical intraepithelial lesions and invasive
carcinomas and hence have been labeled high-riskvirus types [13,14]. It is important
to note, however, that mere infection with a high-risk virus does not imply that a
high-grade lesion is present, or that progression will occur. Most woman who are
infected with these viral types show either no pathologic or low-grade changes
[15,16], and classic morphologic studies show that, in a high proportion (approxi-
mately 90percent) ofpatients, any disease which is presentwill fail toprogress orwill
ultimately regress [7]. Other viral types, such as the 31, 33, and 35 group, seem to
have an intermediate risk, because, while more frequently seen in high-grade genital
dysplasias and carcinomas than types 6 and 11, they are much rarer in the human
population, and less well characterized epidemiologically [11,13,17]. Specific viral
types have also been more highly associated with specific histology and/or clinical
behavior. For instance, HPV type 18 has been implicated in a more rapidly
progressive form of cervical squamous cancer [18], as well as in the small-cell and
adenocarcinoma variants of cervical cancer [19,20,21,22,23]. Infection with the
"high-risk" viruses has been postulated to confer a higher risk of progression from
low- to high-grade lesions. Complete prospective studies to confirm this hypothesis
have not yet been completed, although preliminary data from Syrjanen and co-
workers have suggested that cervical intraepithelial neoplasia (CIN) lesions associ-
ated with HPV type 16 do tend to run a more aggressive course [24]. This point is
particularly important, because data have recently suggested that the most prevalent
virus type found in samples from the cervix may be type 16 [15,25,26].
MOLECULAR EVIDENCE LINKING HPV TO CARCINOGENESIS
The genetic structure of the papillomaviruses has been reviewed extensively
elsewhere [27]. Several key points regarding viral structure and genetic makeup are
important to this discussion. The family of papillomaviruses are small, double-
stranded DNAviruses, consisting of a central core ofDNA, surrounded by an outer
capsid ofviral protein. Viral DNA consists of a covalently closed, circular, double-
stranded molecule of about 7,900 base pairs. The viral genome is organized into
three major areas. The first, representing about 15 percent of the total genome, is a
non-codingsegment known as the longcontrol region (LCR), orupstreamregulatory
region. This region is responsible for much of the DNA replication origination
function and includes several enhancers and promoters of messenger ribonucleic
acid (mRNA) transcription. Thesecondmajorportionoftheviralgenome, represent-
ing about 45 percent of the total, is the early, or E region. This segment contains at
least seven open reading frames (ORFs), each of which codes for one or more
proteins responsible for the maintenance of cellular transformation or viral DNA
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replication [27]. The third portion of the viral genome, comprising 40 percent of the
total, is the late, or L, region, which contains two ORFs coding for viral capsid
proteins.
The body of experimental evidence implicating HPV as a potential agent in the
development of cancer is increasing in size. Portions of the genome from high-risk
viruses have been found in a variety of cervical cancer cell lines. HPV genes from the
high-risk types have been shown to transform a variety of animal and human cell
lines. In addition, extensive studies have been performed to understand the pattern
ofgene expression in these transformed cells and the cells ofclinical carcinomas.
It has been shown that the HPV early coding genes, E6 and E7, are virtually always
present in HPV-related transformed and cancer cells [28]. Both genes appear to be
required together to immortalize human foreskin keratinocytes. E6 alone fails to
elicit a response in the transfected cells, while E7 alone causes hyperproliferation
without immortalization [29]. Transfection of the E6-E7 region of high-risk viruses
alone is sufficient to transform several cell lines [30,31]. In human cancers and
high-grade intraepithelial lesions, HPV DNA is often incorporated into the host
genome [32]. This condition is in distinction to low-grade lesions, where the viral
genome most commonly exists as an episome apart from the host's DNA. This
incorporation of HPV genes has several uniform features. Integration preferentially
disrupts the region of the El and E2 genes. These genes are associated with DNA
replication control and the control of transcription, and, in the process of lineariza-
tion and integration, these genes are damaged. These same genes are critical to the
regulation of E6 and E7 through the adjacent LCR, the three of which are always
retained. Hence the stage is set for poorly controlled replication and transcription of
these particular genes [33]. Homologies of the E7 gene have been identified with the
genes ElA of adenovirus and the large T antigen of the SV40 virus, both known
transforming genes, and suggest the possibility that the E7 gene may play a similar
role in human cervical cancers [34]. In addition, like the protein products of the ElA
and large T antigens, the protein product of the E7 gene can bind to the protein
product (plO5-RB) ofthe retinoblastoma gene, a known tumor suppressor gene, and
this plO5-RB-E7 protein complex has been identified in cell culture [35]. The E7
gene products of HPV types 16 and 18 bind p105-RB with a higher affinity than do
the E7 proteins of HPV types 6 and 11, hence suggesting a greater tumor disposition
for the "high-risk" viral types [35]. Analogously, E6 protein has been found to bind to
cellular protein p53, a protein which also has tumor suppressor activity [36].
Furthermore, there is some evidence to suggest that E7 gene products can interact
with cellular oncogenes, such as ras, to promote cellular transformation [34,37].
Although the molecular evidence, as presented above, is gradually moving toward
implicating the HPV, and specifically the high-risk types, as an effector in the
carcinogenesis process, it must be noted that HPV infection alone is insufficient to
initiate cancer development. Other, as yet undetermined co-factors, potentially
tobacco smoking or other possible viral infections, appear to be necessary for
ultimate neoplastic transformation in humans [3].
METHODS OF TESTING FOR HPV PRESENCE IN CLINICAL SAMPLES
Standard Cytologic and Histologic Examinations
The Papanicolaou smear and surgical biopsy specimens are effective methods of
identifying viral cytopathic effect and secondary features which suggest HPV infec-
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tion, when these changes are present. Molecular biologic evidence supports the
concept that a finding of unequivocal cervical intraepithelial neoplasia (dysplasia,
carcinoma-in-situ), arrived atby standard diagnosticcriteria, implies that HPV DNA
is present in the lesion. Unfortunately, in a large percentage of cases of cytologic
atypia (pure mild nuclear enlargement, and elevated nucleus-to-cytoplasmic ratio of
squamous cells), or the presence ofonlysecondary (non-diagnostic) features ofHPV
infection [hyperkeratosis (HK) and parakeratosis (PK)], the correlation of the
presence of HPV DNA with morphologic features is poor, approaching that seen in
cytologically or histologically normal individuals [12,38,39]. In addition, any assess-
ment of HPV type is not possible on routine light microscopy.
ImmunopathologicAssessment ofHPVPresence
Antibodies raised to bovine papillomavirus capsid antigen have been used exten-
sively to identify the presence of HPV capsid antigen. Unfortunately, immunohis-
tochemistry for HPV shares many of the same limitations as does routine light
microscopy. Because late protein (capsid protein) formation is necessary to provide
antigen for detection in this procedure, generally only low-grade CIN lesions can be
marked with regularity. In several studies of condyloma and low-grade CIN lesions,
only 50-60 percent of cases were positive with immunohistochemistry [10,12,40]. In
our own series of cases, a small percentage of lesions (13 percent) with only
secondary features suggesting HPV presence (HKand PK) were positive forantigen,
and no biopsies of histologically normal tissue were positive [12]. As lesions become
higher-grade, fewer and fewer are positive, in keeping with the previously noted
biology of HPV expression in high-grade lesions [10]. In addition, no ability to assess
HPV type is presently possible with standard immunohistochemistry, although
reagents are currently under investigation which may be able effectively to label
specific protein products ofhigh-riskvirus early genes [41].
NucleicAcidHybridization TechnologyforHPVDetection and Typing
The ability to detect, via nucleic acid hybridization, specific strands ofDNAwhich
code for unique sequences in HPV has been an important force in the advancement
ofour current description ofHPVbiology and forms the basis for the mostcommonly
utilized tests for HPV detection and typing.
There are several methods ofhybridization which can be performed, including dot
blot, Southern blot, and in situ hybridizations. In addition, amplification procedures,
such as the polymerase chain reaction (PCR), have been developed to increase the
sensitivity ofdetection.
All nucleic acid hybridization procedures are based on the principle that two
anti-parallel strands of DNA or ribonucleic acid (RNA) will bind specifically to one
another via hydrogen bonding between complementary base pairs. Probes that bind
to type-specific papillomavirus genetic sequences have been developed, which will
allow not only recognition that HPV DNA (or parts of it) is present, but which can
also allow distinction between the various types of HPV, based on nucleotide
dissimilarities. The concept ofthe stringency of a reaction refers to the factorswhich
favor duplex association; i.e., high-stringency reactions require that base pairs in the
duplex match very closely, while low-stringency reactions require fewer matches to
maintain detectable binding. For instance, a probe specific for sequences unique to
HPV type 6will bindonly to HPV 6 DNAunderconditions ofhighstringencybutwill
117WILBUR AND STOLER
also bind to HPV type 16 under less stringent reaction conditions. Therefore, by
altering the stringency conditions of a particular hybridization study, assays can be
made more or less sensitive and specific. The details of the hybridization and
stringency conditions are extensively reviewed elsewhere and are beyond the scope
ofthis discussion [42,43].
Following the initial specific hybridization reaction between probe and target
DNA or RNA, detection of this interaction must then take place. Probes may be
labeled with a variety of markers, such as radioactive nucleotides (3H, 35S, 32p), for
autoradiographic detection; or with non-radioactive markers, such as biotin, which
allow detection via an enzyme-linked colorimetric assay completely analogous to
those utilized in standard immunohistochemical procedures.
TYPES OF HYBRIDIZATION ASSAYS
DotBlotHybridizations
These assays consist of a sample ofDNA being placed in a specific area of a filter
paper and then incubated with a solution containing the labeled probe, followed by
stringency washes to remove non-hybridized, or incompletely hybridized probe.
Detection ofduplex formation is by exposure ofthe filter paper to X-ray film, in the
case of a radiolabeled probe, or with a colorimetric reaction, in the case of a
non-radioactive probe.
The advantages ofthis assay are ease ofperformance, rapid turnaround time, and
relatively low cost. By utilizing probes directed against specific HPV types, under
stringent reaction conditions, not only detection, but some typing of the virus is
possible. The major disadvantages ofthis assay are that it appears to be less sensitive
than is Southern blotting and some types ofin situ hybridization, and that it lacks the
ability to identify the location ofHPV within the tissue, as the method is destructive
ofthe histologyofthe sample. The mostprominentcommercial effort in HPVtesting
utilizes this type of technology. The test, as commercially available, has shown
moderate sensitivity and excellent specificity [15,26]. One limitation common to all of
the hybridization assays at present is the lackofreadilyavailable probes for all ofthe
viral types associated with genital tract neoplasia. Although probes are available for
the most prevalent viral types, a significant percentage of cases infected with other
viral types mayproduce false-negative assays [15].
Southem BlotHybridizations
This type of assay for the detection of DNA is considered the "gold standard" of
the non-amplified hybridization procedures in terms of sensitivity and specificity.
Studies in patients with documented CIN lesions have shown HPV DNA detection
rates of greater than 90 percent with Southern blot [11,17,44]. In this assay, the
nucleic acid is extracted from the sample and cleaved into smaller fragments with
restriction enzymes. These fragments are then electrophoresed on gels for separa-
tion ofthe fragmentsbased on size. The nucleicacids are then transferred on tofilter
papers and hybridized with probes directed against specific HPV nucleic acid
sequences. Identification ofduplex formation is the same as with dot blots. Southern
blots have the advantage of very high sensitivity and specificity and the ability to
distinguish easily between HPV types by identification of specific restriction pat-
terns; their major disadvantages are that special equipment and expertise are
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required to perform the assay, it is expensive, requires a fairly large sample, and, like
dot blots, is destructive of the tissue, not allowing HPV localization and correlation
with histology.
In Situ Hybridization (ISH)
In this procedure, the hybridization reaction is performed directly on the tissue
section or cytologic specimen. The procedure is therefore an "in situ dot blot," and
visualization of duplex formation is by either autoradiography (when radiolabeled
probes are used) or colorimetric visualization, as in immunohistochemical analyses.
The major advantage to this procedure is the ability tovisualize the exact location of
the HPV nucleic acid and therefore to correlate the exact histology with which it is
associated, as well as allowing individual positive cells to be identified against a
background ofnegative cells. In addition, the sensitivity and specificity are compara-
ble to Southern blot when the more sensitive radiolabeled assays are utilized [12].
For such assays, the limit of sensitivity has been theoretically determined to be
approximately 25 whole genomic equivalents per cell [42]. Hence, it is apparent that
these procedures will fail to identify very low-level infected states. Generally,
commercially available, non-isotopic ISH kits have been shown to be less sensitive
than isotopic assays; however, several recently published reports have shown im-
proved sensitivity with commercially available, non-isotopic probe kits [45,46,47]. In
situhybridization can alsobeperformed onarchival, fixed-processed tissue, eliminat-
ing the. need for the fresh tissue necessary in the above-mentioned hybridization
assays. The major disadvantage ofthe procedure is that, in its most sensitive form, it
is time- and labor-intensive, although commercially available kits have more recently
offered increased simplicity.
Amplification Technology
Newly developed methods for amplification of low-level DNA signals have re-
cently been applied to the detection of HPV DNA. The most common procedure is
the polymerase chain reaction (PCR) [48]. This procedure most often utilizes a
thermostable DNApolymerase known as Taq,which, through the use ofnucleic acid
primers directed against specific target DNA sequences, allows exponential produc-
tion of copies of target DNA, so that identification by the labeled probe can be
achieved. Theoretically, this procedure is exquisitely sensitive, being able to identify
single copygenes. The price forthis high sensitivity is the high risk ofcontamination,
leading to false-positive results. Hence, extreme caution must be exercised in
specimen handling and in the use ofcontrol material. This procedure can be run on
both fresh and recently fixed-archival tissues [15,49,50,51]. The sensitivity for detec-
tion of HPV DNA by PCR appears to be the highest of all the above-mentioned
techniques. Bauer et al. [15] showed that, when compared with dot blot hybridiza-
tion, PCR identified four times as many infected patients. The major advantage of
PCR in this study was the procedure's ability to identifyviral types forwhich probes
were not available in the dot blot assay.
CLINICAL USE OF TESTING FOR HUMAN PAPILLOMAVIRUS
The simplistic approach to HPVtestingwould dictate that, ifall patientswhowere
infected with HPV, and in particular those infected with one of the intermediate or
high-riskviruses, couldbe identified, these patients could be closelyfollowed, and/or
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treated, with the HPV infectionbeing ablated prior to the sequential development of
dysplasias and invasive cancers. Under this scenario, mass screening for HPV would
be a very important tool in the prevention of cervical cancer. Unfortunately, at the
present time there are no effective means oftreating or eradicating HPV infections.
Effective treatments are available only tocontrol CINlesionswhenthey are detected
by cytology or colposcopy. In addition, for a screening test to be effective, it needs to
be very sensitive and preferably inexpensive [52]. In situations of relatively low
disease prevalence (e.g., cervical cancer and its precursors), the test needs to be very
specific to have a high predictive value for the disease in question. There is early
evidence to suggest that, in fact, the most widely applicable test (least expensive and
technically simplest), the dot blot hybridization, may not be as sensitive as is
necessary. Several studies performing either dot blot [26,53] or Southern blot [39]
screens on patient populations have found detection rates ranging from as low as 40
percent to as high as 80 percent of patients who have some evidence, either current
or past cytologic abnormality, indicative of HPV infection. Many of these patients
undoubtedly had eradicative procedures and were no longer infected, but presum-
ably many had levels of HPV DNA below detection limits for the test, or HPV types
which were not being probed for in the assay utilized. By comparison, studies
utilizing PCR amplification technology have shown detection rates consistently
greater than 80 percent in similar patient populations who have cytologic evidence of
HPV infection [15,54]. In addition, it appears that the prevalence of HPV infection
in the community among some epidemiologically defined high-risk populations may
be as high as 80 percent [55], although it appears that reasonable estimates range
from less than 5 percent in private patient populations to as high as 46 percent in
sexually transmitted disease clinics and student health service populations
[15,16,26,53]. Exact prevalence figures are unknown at present because broad-based
population studies, usinggold-standard techniques, have notyet been reported, and,
clearly, prevalence data will vary considerably, dependent on the population studied
and on the methods utilized in screening. On the other hand, evidence obtained over
many years utilizing the Pap smear, colposcopy, and biopsy has shown that the
prevalence of cytologic, colposcopic, and histologic abnormalities of CIN in the
population, at 2-3 percent [7,24,56], is significantly lower than what has been
estimated for the prevalence of HPV infection. Therefore, it appears that a large
pool of "infected" individuals exists, who have, at the present time, no identifiable
changes in the cervix. Syrjanen [24] has termed these types of infections as latent
(only molecular biologic evidence of HPV DNA, without cytologic or colposcopic
evidence of disease), or subclinical (molecular biologic evidence, plus minimal or
inconclusive cytologic or colposcopic evidence of disease). Under the scenario of
molecular biologic screening, these groups of patients would create a significant
dilemma for the gynecologist, who must then decide how to utilize effectively this
molecularbiologic evidence ofinfection without clinical disease. The natural history
of the HPV DNA-positive, disease manifestation-negative state is poorly known at
the present time. No estimate can be made of the number of these individuals who
will ever proceed to clinically significant illness (i.e., HPV DNA testing lacks
specificity for the actual neoplastic disease process). In addition, classicmorphologic
studies have clearly shown a high regression rate at all levels ofCIN, suggesting that,
even when a lesion becomes manifest, there still exists a significant number of
patients who will never progress to invasive cancer [7]. Other, as yet unknown,
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factors must be involved in this progression. Therefore, mass screening for HPV
DNA would create the potential for overzealous treatment, overwhelmed gynecolo-
gists, unnecessary patient anxiety, and tremendous cost, all for undocumented
benefit [57]. In addition, because the test may lack sufficient sensitivity, and the
prevalence of infection (not clinical disease) appears to be high in the population,
there is the potential for significant numbers of infected individuals to be missed by
anybut the most sensitive tests.
An augmented screening approach, which has been suggested, is to perform HPV
typing on all HPV DNA-positive individuals. This procedure would presumably
serve to identify the patients who are postulated to represent a group at higher risk
for progression and hence would need closer follow-up and/or treatment. In this
scenario, a substantial number of patients would be placed in the HPV high-risk
type-positive, disease manifestation-negative group, of which the natural history is
again poorly known.
Therefore, it appears that, atthe present time, the datawould suggest an approach
ofscreening, following, and treating patients usingwell-established criteria based on
cytologic, colposcopic, or histologic abnormalities, about which the natural history is
better understood. In aprospective studyofacohort ofuntreated patients in Finland
found to have clinical infection (molecular biologic evidence of HPV infection, plus
conclusive cytologic and colposcopic evidence of CIN), the most significant factors
affecting the rate ofprogression ofdiseasewere the histologic grade ofthe abnormal-
ity at the time of the first biopsy, the degree of cellular atypia on the initial Pap
smear, and the presence ofHPV type 16 [24]. The overall progression and regression
rates for CIN lesions in this study closely paralleled those rates well known from
classic cytologic studies, suggesting again that the presence of a positive HPV DNA
assay may not be adding significant information beyond routine cytology. The latter
finding of the association in this group, between the presence of HPV type 16 and
progression ofdisease, may addweight to the hypothesis that HPV type 16 latent and
subclinical infections mayalsobe at higher riskfor progression to clinical disease, but
no studies have yet been completed to confirm this conjecture. Also, the natural
history of HPV type 16 histologically confirmed CIN lesions, by inference from
classic data, may include a significant number of regressors [24]. In addition, cancers
and high-grade dysplastic lesions have been known to occur, albeit infrequently, with
"low-risk" viral types [58,59]. Finally, because HPV type 16 may be the most
prevalent virus in the cervix, it is therefore the most commonly expected result of
typing on samples from this site which test positive for HPV [14,15,25,26].
The problem of rapidly progressive cervical cancer [18] and its association with
HPV type 18 may eventually warrant an approach which selectively screens for this
viral type in the population, but further characterization of this disease entity must
first take place.
At present, the only well-founded indication for performance of an identification
and/or typing test for HPV in the clinical setting is under circumstances in which the
result will guide follow-up and further patient management. If one believes that
lesions of CIN I or higher require eradication, then HPV testing has no significant
role when such lesions are identified by cytologic or colposcopic examination. In the
case ofthe atypias, or minimally abnormal results on Pap smear, there hasbeen some
interest and rationale for HPV testing. In many cases of atypia, the cause is not
related to infection by HPV but may be due to other inflammatory/infectious
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conditions which are not pre-cancerous. Therefore, the absence of HPV, or the
presence of a low-risk HPV type might warrant continued cytologic follow-up,
whereas the presence of HPV, or of a high-risk HPV type, might warrant more
aggressive investigation/follow-up or treatment. In this scenario, the test could be
useful for choosing between alternatives in patient management. Even on this point
there is significant disagreement among pathologists and among clinicians. Some
would follow minimal Pap smearchangesbycytologyregardless ofHPV status,while
others would perform colposcopy on all patients with these changes for fear of
missing a more serious lesion. As the detection of HPV DNA is poorly correlated
with equivocal morphologic changes, the decision to follow versus colposcope the
patient isbest made on the basis ofclinicaljudgment.
SUMMARY
At the present time, the only plausible clinical indication for the performance of
an HPV DNA identification and/or viral typing relates to minimal or low-grade
cytologic abnormalities which may be managed in differing ways, dependent on the
outcome ofthe test. Further screening indications, particularly in high-risk epidemi-
ologic populations, may be forthcoming with prospective, longitudinal studies,
detailing the natural history of the HPV-positive, disease manifestation-negative
patient (latent or subclinical infections), and a more thorough understanding ofthe
epidemiology of"high-risk" virus-infected patients.
In the future, additional HPV-related screening tests,which havebetterpredictive
value for, or correlation with, cervical pathology, will need to be developed. These
might include assays for HPV messages or gene products which would indicate the
presence of active viral genetic activity. Such signals might better correlate with the
presence of clinical lesions or high likelihood of progression, rather than with the
simple presence ofviral DNA.
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